You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
1. JAMA. 2007 Feb 14;297(6):603-10. doi: 10.1001/jama.297.6.603.

Reduction of iron stores and cardiovascular outcomes in patients with peripheral 
arterial disease: a randomized controlled trial.

Zacharski LR(1), Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka 
DJ, Ozaki CK, Lavori PW.

Author information:
(1)White River Junction VA Medical Center, Research Service, Department of 
Veterans Affairs Medical Center, White River Junction, VT 05001, USA. 
leo.r.zacharski@dartmouth.edu

Comment in
    JAMA. 2007 Feb 14;297(6):639-41. doi: 10.1001/jama.297.6.639.
    JAMA. 2007 May 16;297(19):2075-6; author reply 2076. doi: 
10.1001/jama.297.19.2075-b.
    JAMA. 2007 May 16;297(19):2075; author reply 2076. doi: 
10.1001/jama.297.19.2075-a.

CONTEXT: Accumulation of iron in excess of physiologic requirements has been 
implicated in risk of cardiovascular disease because of increased iron-catalyzed 
free radical-mediated oxidative stress.
OBJECTIVE: To test the hypothesis that reducing body iron stores through 
phlebotomy will influence clinical outcomes in a cohort of patients with 
symptomatic peripheral arterial disease (PAD).
DESIGN, SETTING, AND PATIENTS: Multicenter, randomized, controlled, 
single-blinded clinical trial based on the Iron (Fe) and Atherosclerosis Study 
(FeAST) (VA Cooperative Study #410) and conducted between May 1, 1999, and April 
30, 2005, within the Department of Veterans Affairs Cooperative Studies Program 
and enrolling 1277 patients with symptomatic but stable PAD. Those with 
conditions likely to cause acute-phase increase of the ferritin level or with a 
diagnosis of visceral malignancy within the preceding 5 years were excluded. 
Analysis was by intent-to-treat.
INTERVENTION: Patients were assigned to a control group (n = 641) or to a group 
undergoing reduction of iron stores by phlebotomy with removal of defined 
volumes of blood at 6-month intervals (avoiding iron deficiency) (n = 636), 
stratified by hospital, age, and baseline smoking status, diagnosis of diabetes 
mellitus, ratio of high-density to low-density lipoprotein cholesterol level, 
and ferritin level.
MAIN OUTCOME MEASURES: The primary end point was all-cause mortality; the 
secondary end point was death plus nonfatal myocardial infarction and stroke.
RESULTS: There were no significant differences between treatment groups for the 
primary or secondary study end points. All-cause deaths occurred in 148 patients 
(23%) in the control group and in 125 (20%) in the iron-reduction group (hazard 
ratio (HR), 0.85; 95% confidence interval (CI), 0.67-1.08; P = .17). Death plus 
nonfatal myocardial infarction and stroke occurred in 205 patients (32%) in the 
control group and in 180 (28%) in the iron-reduction group (HR, 0.88; 95% CI, 
0.72-1.07; P = .20).
CONCLUSION: Reduction of body iron stores in patients with symptomatic PAD did 
not significantly decrease all-cause mortality or death plus nonfatal myocardial 
infarction and stroke.
TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00032357.

DOI: 10.1001/jama.297.6.603
PMID: 17299195 [Indexed for MEDLINE]
</reference>

<statements>
1. The Veterans Affairs Cooperative Study No. 410, known as the Iron (Fe) and Atherosclerosis Study (FeAST), formally evaluated this hypothesis
2. FeAST randomized 1,277 patients with symptomatic peripheral arterial disease to either calibrated phlebotomy (drawing blood at 6-month intervals to maintain ferritin levels between 25 and 50 ng/mL without inducing anemia) or standard care
3. Over a mean follow-up of 4.5 years, the trial yielded neutral results: all-cause mortality occurred in 20% of the iron-reduction cohort versus 23% of controls (hazard ratio [HR] 0.85, 95% CI [0.67, 1.08], p=0.17), and the composite secondary endpoint of death, nonfatal myocardial infarction, and stroke showed no significant difference (HR 0.88, 95% CI [0.72, 1.07], p=0.20)
4. Although exploratory post-hoc subgroup analyses suggested potential reductions in mortality among younger patients (ages 43-61) and active smokers, the primary outcome demonstrated that routine iron reduction does not reduce broad macrovascular events in atherosclerotic populations
5. Iron Depletion (Phlebotomy): FeAST Trial (n=1,277)
6. Iron Depletion (Phlebotomy): Neutral for primary vascular endpoints (HR 0.85, p=0.17)
7. Iron Depletion (Phlebotomy): Risk of iatrogenic microcytic anemia; poor compliance with serial phlebotomy
8. Trial Name: **FeAST** (2007)
9. Target Cohort: Symptomatic Peripheral Arterial Disease
10. Interventions Evaluated: Serial phlebotomy (target ferritin 25–50 ng/mL) vs. Control
11. Primary Outcome Endpoint: All-cause mortality
12. Primary Result & Hazard Ratio: **Neutral:** \(\text{HR } 0.85\) (\(95\%\text{ CI } [0.67, 1.08]\), \(p=0.17\))
13. Conversely, therapeutic iron depletion via phlebotomy carries risks of over-titration
14. In the FeAST trial, maintaining ferritin levels between 25 and 50 ng/mL required regular laboratory monitoring to prevent excessive reduction of total hemoglobin, which risks precipitating iatrogenic iron-deficiency anemia, tissue hypoxia, and exacerbations of baseline angina or intermittent claudication
15. Therapeutic iron depletion via phlebotomy is indicated solely for hereditary hemochromatosis with iron-overload cardiomyopathy, and has no established therapeutic role in broad coronary or peripheral vascular disease
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.